NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
|
3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
|
|
|
IUPAC Traditional name
|
furazolidone
|
3-[(E)-[(5-nitrofuran-2-yl)methylidene]amino]-1,3-oxazolidin-2-one
|
furazolum
|
|
|
Brand Name
|
Bifuron
|
Corizium
|
Coryzium
|
Diafuron
|
Enterotoxon
|
Fiurox aerosol powder
|
Furall
|
Furaxon
|
Furaxone
|
Furazol
|
Furazolidine
|
Furazolidon
|
Furazon
|
Furidon
|
Furovag
|
Furox
|
Furoxal
|
Furoxane
|
Furoxon
|
Furoxone
|
Furoxone Liquid
|
Furoxone Swine Mix
|
Furozolidine
|
Giardil
|
Giarlam
|
Medaron
|
Neftin
|
Nicolen
|
Nifulidone
|
Nifuran
|
Nifurazolidone
|
Nitrofuroxon
|
Optazol
|
Ortazol
|
Puradin
|
Roptazol
|
Sclaventerol
|
Tikofuran
|
Topazone
|
Trichofuron
|
Tricofuron
|
Tricoron
|
Trifurox
|
Viofuragyn
|
|
|
Synonyms
|
3-[[(5-Nitro-2-furanyl)methylene]amino]-2-oxazolidinone
|
3-[(5-Nitrofurfurylidene)amino]-2-oxazolidinone
|
Diafuron
|
Furaxon
|
Furazol
|
Furazolidon
|
Giardil
|
Giarlam
|
Ortazol
|
Puradin
|
Roptazol
|
Tikofuran
|
Trifurox
|
3-{[(5-nitrofuran-2-yl)methylidene]amino}-1,3-oxazolidin-2-one
|
Nitrofurazolidone
|
Nitrofurazolidonum
|
USAF EA-1
|
Furazolidone
|
Furoxone
|
Nifulidone
|
Neftin
|
3-(5-nitrofurfurylideneamino)-2-oxazolidinone
|
3-[[(5-Nitro-2-furanyl)methylene]-amino]-2-oxazolidinone
|
3-(5-nitrofurfurylideneamino)-2-oxazolidinone
|
N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone
|
Furovag
|
Furoxane
|
Medaron
|
Topazone
|
Furazolidone
|
3-(5-硝基呋喃甲叉氨基)-2-噁唑烷酮
|
呋喃唑酮
|
|
|
CAS Number
|
|
EC Number
|
|
MDL Number
|
|
Beilstein Number
|
|
PubChem SID
|
|
PubChem CID
|
|
ATC CODE
|
|
CHEMBL
|
|
Chemspider ID
|
|
DrugBank ID
|
|
KEGG ID
|
|
Unique Ingredient Identifier
|
|
Wikipedia Title
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
H Acceptors
|
4
|
H Donor
|
0
|
LogD (pH = 5.5)
|
0.8699244
|
LogD (pH = 7.4)
|
0.8699244
|
Log P
|
0.8699244
|
Molar Refractivity
|
50.081 cm3
|
Polarizability
|
18.65204 Å3
|
Polar Surface Area
|
98.18 Å2
|
Rotatable Bonds
|
3
|
Lipinski's Rule of Five
|
true
|
Log P
|
0.15
|
LOG S
|
-2.79
|
Solubility (Water)
|
3.64e-01 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Safety Information
Pharmacology Properties
Product Information
Bioassay(PubChem)
Solubility
|
40 mg/L
|
Show
data source
|
DMSO
|
Show
data source
|
|
Apperance
|
Yellow Solid
|
Show
data source
|
|
Melting Point
|
247-249°C
|
Show
data source
|
254 - 256°C (dec.)
|
Show
data source
|
254-256°C dec.
|
Show
data source
|
|
Hydrophobicity(logP)
|
-0.038
|
Show
data source
|
0.9
|
Show
data source
|
|
Storage Condition
|
-20°C Freezer
|
Show
data source
|
Room Temperature (15-30°C), Protect from light
|
Show
data source
|
|
Storage Warning
|
Light Sensitive
|
Show
data source
|
|
RTECS
|
RQ3675000
|
Show
data source
|
|
European Hazard Symbols
|
Harmful (Xn)
|
Show
data source
|
|
MSDS Link
|
|
German water hazard class
|
3
|
Show
data source
|
|
Risk Statements
|
62
|
Show
data source
|
68
|
Show
data source
|
|
Safety Statements
|
36
|
Show
data source
|
36/37
|
Show
data source
|
|
TSCA Listed
|
是
|
Show
data source
|
|
GHS Pictograms
|
|
Show
data source
|
|
GHS Signal Word
|
Warning
|
Show
data source
|
|
GHS Hazard statements
|
H341-H303
|
Show
data source
|
H361
|
Show
data source
|
|
GHS Precautionary statements
|
P281
|
Show
data source
|
P281-P201-P312-P308+P313-P405-P501A
|
Show
data source
|
|
Personal Protective Equipment
|
dust mask type N95 (US), Eyeshields, Gloves
|
Show
data source
|
Eyeshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
|
Show
data source
|
|
Admin Routes
|
Oral-Local
|
Show
data source
|
|
Mechanism of Action
|
Interferes with several bacterial Enzyme systems
|
Show
data source
|
|
Purity
|
95%
|
Show
data source
|
97%
|
Show
data source
|
98%
|
Show
data source
|
|
Grade
|
VETRANAL™, analytical standard
|
Show
data source
|
|
Certificate of Analysis
|
|
Application(s)
|
.
|
Show
data source
|
Activity against: Escherichia coli; Staphylococcus; Proteus; Giardia lamblia.; Enterobacter aerogenes
|
Show
data source
|
Antiseptic, antiprotozoal and antibacterial agent
|
Show
data source
|
|
Empirical Formula (Hill Notation)
|
C8H7N3O5
|
Show
data source
|
|
DETAILS
DETAILS
MP Biomedicals
DrugBank
Wikipedia
Sigma Aldrich
TRC
DrugBank -
DB00614
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514) |
Indication |
For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms. |
Pharmacology |
Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms. |
Toxicity |
Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors. |
Affected Organisms |
• |
Microbes (bacteria, parasites) |
|
Biotransformation |
Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione. |
Absorption |
Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration |
Half Life |
10 minutes |
External Links |
|
|
Sigma Aldrich -
F9505
|
Application Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA, which leads to the gradual inhibition of monoamine oxidase. It is used to treat anorexia and antagonism of thiamin utilization in poultry1. Furazolidone increases thapsigargin-sensitive Ca2+-ATPase in chick cardiac myocytes2. Biochem/physiol Actions Furazolidone and its generated free radicals, may bind to DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug, which results in high levels of mutations (transitions and transversions) in the bacterial chromosome. Its mechanism of action minimizes the development of resistant organisms. Furazolidone is a monoamine oxidase (MAO) inhibitor. It increases thapsigargin-sensitive Ca2+-ATPase in chick cardiac myocytes2. Furazolidone is a monoamine oxidase (MAO) inhibitor and is used as a DNA interstrand cross-linking agent. |
Sigma Aldrich -
46297
|
Legal Information VETRANAL is a trademark of Sigma-Aldrich Co. LLC |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Yurchenco, J.A., et al.: Antimicrob. Chemother., 3, 1035 (1953)
- • Sharma, C., et al.: J. Clin. Microbiol., 36, 756 (1953)
- • Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 40B, (nmr)
- • Yurchenco, J.A. et al., Antibiot. Chemother. (Washington, D.C.), 1953, 3, 1035, (pharmacol)
- • Gever, G. et al., J.A.C.S., 1955, 77, 2277; 2282, (synth)
- • Rogers, G.S. et al., Antibiot. Chemother. (Washington, D.C.), 1956, 6, 231, (pharmacol)
- • Chamberlain, R.E., J. Antimicrob. Chemother., 1976, 2, 325, (rev)
- • Cohen, S.M., Carcinog. - Compr. Surv., (ed. Bryan, G.T.), Raven Press, N.Y., 1978, 171-231, (tox)
- • Tatsumi, K. et al., Chem. Pharm. Bull., 1982, 30, 3435, (metab, tox)
- • IARC Monog., 1983, 31, 141; Suppl. 7, 63, (rev, tox)
- • Ali, B.H., Vet. Res. Commun., 1983, 6, 1, (rev, pharmacol)
- • Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 837, (synonyms)
- • Ali, B.H., Gen. Pharmacol., 1989, 20, 557, (rev)
- • Vroomen, L.H.M. et al., Drug Metab. Rev., 1990, 22, 663
- • Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 514
- • Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, NGG500
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent